These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

249 related articles for article (PubMed ID: 30414950)

  • 1. Strategies for brain-targeting liposomal delivery of small hydrophobic molecules in the treatment of neurodegenerative diseases.
    Wang ZY; Sreenivasmurthy SG; Song JX; Liu JY; Li M
    Drug Discov Today; 2019 Feb; 24(2):595-605. PubMed ID: 30414950
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting nanoparticles across the blood-brain barrier with monoclonal antibodies.
    Loureiro JA; Gomes B; Coelho MA; do Carmo Pereira M; Rocha S
    Nanomedicine (Lond); 2014 Apr; 9(5):709-22. PubMed ID: 24827845
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Brain drug delivery systems for neurodegenerative disorders.
    Garbayo E; Ansorena E; Blanco-Prieto MJ
    Curr Pharm Biotechnol; 2012 Sep; 13(12):2388-402. PubMed ID: 23016644
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Perspectives on Development and Regulation of Therapeutic Products for CED-Based Therapy of Neurodegenerative Diseases.
    Somayaji MR
    Curr Pharm Biotechnol; 2016; 17(6):495-512. PubMed ID: 26517332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting New Candidate Genes by Small Molecules Approaching Neurodegenerative Diseases.
    Fan HC; Chi CS; Cheng SN; Lee HF; Tsai JD; Lin SZ; Harn HJ
    Int J Mol Sci; 2015 Dec; 17(1):. PubMed ID: 26712747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges and opportunities in CNS delivery of therapeutics for neurodegenerative diseases.
    Barchet TM; Amiji MM
    Expert Opin Drug Deliv; 2009 Mar; 6(3):211-25. PubMed ID: 19290842
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanobiomaterials' applications in neurodegenerative diseases.
    Silva Adaya D; Aguirre-Cruz L; Guevara J; Ortiz-Islas E
    J Biomater Appl; 2017 Feb; 31(7):953-984. PubMed ID: 28178902
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nanoparticle-mediated brain drug delivery: Overcoming blood-brain barrier to treat neurodegenerative diseases.
    Saraiva C; Praça C; Ferreira R; Santos T; Ferreira L; Bernardino L
    J Control Release; 2016 Aug; 235():34-47. PubMed ID: 27208862
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders.
    Nguyen KT; Pham MN; Vo TV; Duan W; Tran PH; Tran TT
    Curr Drug Metab; 2017; 18(9):786-797. PubMed ID: 28124594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Exosomes as therapeutic and drug delivery vehicle for neurodegenerative diseases.
    Nouri Z; Barfar A; Perseh S; Motasadizadeh H; Maghsoudian S; Fatahi Y; Nouri K; Yektakasmaei MP; Dinarvand R; Atyabi F
    J Nanobiotechnology; 2024 Aug; 22(1):463. PubMed ID: 39095888
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic potential of controlled drug delivery systems in neurodegenerative diseases.
    Popovic N; Brundin P
    Int J Pharm; 2006 May; 314(2):120-6. PubMed ID: 16529886
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Growing synergy of nanodiamonds in neurodegenerative interventions.
    Saraf J; Kalia K; Bhattacharya P; Tekade RK
    Drug Discov Today; 2019 Feb; 24(2):584-594. PubMed ID: 30408527
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Current Small Molecule-Based Medicinal Chemistry Approaches for Neurodegeneration Therapeutics.
    Sanghai N; Vuong B; Burak Berk A; Afridi MSK; Tranmer GK
    ChemMedChem; 2024 May; 19(9):e202300705. PubMed ID: 38329887
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanotechnology-based Targeting of Neurodegenerative Disorders: A Promising Tool for Efficient Delivery of Neuromedicines.
    Rajpoot K
    Curr Drug Targets; 2020; 21(8):819-836. PubMed ID: 31906836
    [TBL] [Abstract][Full Text] [Related]  

  • 15. On the Neuroprotective Effects of Naringenin: Pharmacological Targets, Signaling Pathways, Molecular Mechanisms, and Clinical Perspective.
    Nouri Z; Fakhri S; El-Senduny FF; Sanadgol N; Abd-ElGhani GE; Farzaei MH; Chen JT
    Biomolecules; 2019 Nov; 9(11):. PubMed ID: 31684142
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neurotrophic factors and neurodegenerative diseases: a delivery issue.
    Ruozi B; Belletti D; Bondioli L; De Vita A; Forni F; Vandelli MA; Tosi G
    Int Rev Neurobiol; 2012; 102():207-47. PubMed ID: 22748832
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Improving drug delivery technology for treating neurodegenerative diseases.
    Choonara YE; Kumar P; Modi G; Pillay V
    Expert Opin Drug Deliv; 2016 Jul; 13(7):1029-43. PubMed ID: 26967508
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advanced nanoparticle strategies for optimizing RNA therapeutic delivery in neurodegenerative disorders.
    Naimi N; Seyedmirzaei H; Hassannejad Z; Soltani Khaboushan A
    Biomed Pharmacother; 2024 Jun; 175():116691. PubMed ID: 38713941
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel nanomaterials for clinical neuroscience.
    Gilmore JL; Yi X; Quan L; Kabanov AV
    J Neuroimmune Pharmacol; 2008 Jun; 3(2):83-94. PubMed ID: 18210200
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.